GILD Price Prediction Next Week
Gilead Sciences (GILD) Stock Price Prediction
Based on the analysis of news and technical indicators, the predicted stock price for Gilead Sciences (GILD) in the next trading week is $112.
Buy or Sell Recommendation
Buy GILD if it breaks above the resistance level of $112, as this could indicate a bullish trend.
GILD Similar Chart Price Prediction
The price of GILD is predicted to go up 20.5%, based on the high correlation periods with CLW. The similarity of these two price pattern on the periods is 95.85%.
GILD
CLW
Up: 20.5%Similarity: 95.85%
GILD Revenue Forecast
GILD EPS Forecast
GILD FAQs
What is GILD revenue forecast for next quarter？
What is GILD eps forecast for next quarter？
GILD VS S&P500
Gilead markets several single-tablet regimens for HIV, and its next-generation products with better long-term safety profiles, led by Biktarvy, are boosting the company's market share.
Guidelines that aim to improve diagnosis and treatment rates, and new prophylaxis use, provide strong tailwinds for growth in HIV.
Gilead's pipeline could begin to see more blockbuster launches, particularly if Trodelvy is able to see solid data expanding its approved indication.
GILD Analyst's Forecast
Chris Schott
JP Morgan
Buy
2025-03-27
Price Target
$120 → $130
Upside
+16.98%
JPMorgan says that while the Wall Street Journal's report on potential Centers for Disease Control and Prevention funding cuts for HIV prevention is "clearly not a positive" for Gilead, any cuts would not impact access to pre-exposure prophylaxis. The CDC is not responsible for providing and reimbursing PrEP drugs, but rather works on PrEP research and education, the analyst tells investors in a research note. JPMorgan still sees lenacapavir in PrEP as a meaningful growth driver for GGilead as coverage ramps in 2026, with an even larger role for versions of lenacapavir in long-acting treatment combinations. As such, the firm does not see the headlines as meaningfully impacting the Gilead story. JPMorgan keeps an Overweight rating on Gilead.
Hartaj Singh
Oppenheimer
Buy
2025-03-04
Price Target
$115 → $132
Upside
+15.04%
Brian Abrahams
RBC Capital
Hold
2025-02-12
Price Target
$84 → $90
Downside
-12.88%
